-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

Benzinga·08/05/2026 18:31:52
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.